Sciverse Solutions Pvt. Ltd., headquartered in Pune, is transforming global healthcare with its pioneering, AI-powered point-of-care (POC) technologies. Combining clinical empathy with engineering precision, the company brings together experts in clinical AI, embedded systems, microfluidics, and cloud platforms to deliver advanced diagnostics that are accessible, accurate, and lightning-fast.
At the heart of Sciverse’s innovation is MyCount Xpress—a game-changing device that delivers lab-grade, 5-part differential CBC results from a mere finger-prick sample. MyCount Xpress has been co-developed in collaboration with Mylab Discovery Solutions, a renowned Indian diagnostics company acclaimed for its critical contributions during the COVID-19 pandemic. It requires no calibration and delivers results within minutes. Building on this momentum, Scilisa introduces a groundbreaking bead-based digital ELISA platform. It offers ultra-sensitive, multiplex biomarker detection—ideal for deployment in remote, decentralized environments. Complementing these diagnostics is Scivision.ai, a no-code AI platform for microscopy image analysis. Seamlessly integrated with Sciverse’s proprietary hardware, such as Scicam and Analyzer, it allows users to create deep-learning models with remarkable ease—no coding required.
Yet, Sciverse’s offerings extend far beyond products. The company provides comprehensive, end-to-end solutions—spanning AI and software development, ergonomic device design, and full-scale contract manufacturing. This includes capabilities in microfluidics, PCB design, and biosensor fabrication.
Guided by a mission anchored in clinical empathy, Sciverse is not just building technology—it is democratizing diagnostics, making precision healthcare universally accessible.
In an exclusive conversation with The Interview World at India Health 2025, Rahul Singh, Founder and Managing Director of Sciverse, dives deep into the company’s core offerings. He reveals the clinical-grade accuracy of their test results, discusses the affordability and scalability of their devices, outlines the next wave of technological breakthroughs, and shares a bold vision for global growth and impact.
Here are the key takeaways from his thought-provoking exchange.
Q: Can you elaborate on the specific products and services that Sciverse offers within the healthcare sector, and how they are addressing key challenges or gaps in the industry?
A: We are an AI-first company revolutionizing point-of-care diagnostics. At the forefront of our innovations is MyCount Xpress—India’s first express CBC analyzer that delivers a five-part differential CBC using just a finger-prick sample.
Traditionally, CBC tests required venous blood draws—a difficult process, especially for young children. Imagine a 6-, 7-, or 10-year-old child undergoing a blood test. Drawing venous samples can be traumatic and logistically challenging. Our technology eliminates that hurdle.
The same applies to pregnant women, where regular platelet monitoring is essential. Frequent venous blood draws can be uncomfortable and impractical. Considering that a significant percentage of Indian women are anemic, monthly monitoring through a simple finger-prick significantly enhances patient compliance and healthcare outcomes.
But we didn’t stop there. We are now integrating C-reactive protein (CRP) testing into the platform. This combination—CBC + CRP—gives clinicians a powerful tool to differentiate between viral and bacterial infections. With this, doctors can prescribe antibiotics more judiciously, avoiding overmedication and ensuring targeted treatment.
Our vision is clear: bring diagnostics directly to the end user, with speed, accuracy, and ease.
In parallel, we’ve built Scivision.ai, a breakthrough no-code AI platform for specimen image analysis. It’s the only system that requires as few as 5 to 10 microscope images to train an algorithm. Whether it’s soil samples, semen analysis, or pharmaceutical microscopy, Scivision allows users to build AI models without any coding or data science expertise.
Just identify the targets once—and the next time, the system detects them automatically. No AI engineers, no domain experts—just plug-and-play intelligence at the edge.
Moreover, we offer end-to-end services for point-of-care diagnostics. Whether you have an idea for a wearable device, a pediatric test, or a new home-based diagnostic tool, we can bring it to life. Our in-house team of specialists covers optics, cartridge design, software engineering, and clinical AI.
Currently, we’re a passionate team of 30–35 professionals—scientists, technologists, and AI experts—hailing from premier institutes like IIT Bombay and other IITs across India. Together, we are building the future of decentralized diagnostics, one breakthrough at a time.
Q: What is the demonstrated accuracy of your diagnostic tests, and how do they benchmark against traditional diagnostic methods in terms of reliability and clinical outcomes?
A: Our flagship product, MyCount Xpress, has already received regulatory approval from both the Central Drugs Standard Control Organisation (CDSCO) in India and the Brazilian Health Regulatory Agency (Anvisa). These certifications mark significant milestones, validating the product’s safety, reliability, and clinical utility in two major healthcare markets.
We are now actively pursuing approval from the South African Health Products Regulatory Authority (SAHPRA) and have initiated the evaluation process for USFDA clearance as well. These steps are part of our broader strategy to make MyCount Xpress a globally recognized diagnostic solution.
In terms of clinical accuracy, MyCount Xpress has been rigorously validated against the Sysmex XN series, a gold-standard predicate device in hematology. This ensures that our results consistently meet high diagnostic benchmarks, offering lab-grade precision at the point of care.
Q: Are you positioning your offering as a service-based solution, a product for direct deployment in labs, or a combination of both?
A: We are a research-driven technology company focused on pioneering breakthrough innovations. Our core strength lies in developing advanced diagnostic technologies. To bring these solutions to market at scale, we strategically collaborate with channel partners and commercial allies who specialize in market deployment and distribution.
Q: How affordable is this technology for testing providers, especially in cost-sensitive markets?
A: Our goal is to make this technology truly affordable, ensuring it reaches end-users across every segment of India. We believe equitable access to advanced diagnostics should not be a privilege—it should be a standard.
To achieve this, we focus on developing the technology at an optimized cost. From there, our channel partners play a vital role. By leveraging their distribution networks and market reach, they can deliver our solutions to the end-users at an accessible price point.
Ultimately, this collaborative model helps bridge the gap between innovation and impact—bringing cutting-edge healthcare within everyone’s reach.
Q: What are your plans for the next phase of innovation over the next 5 to 10 years, and how do you envision evolving these products to meet future healthcare needs?
A: Over the next 5 to 10 years, we aim to deepen our focus on diabetes management—a space where we’re already driving cutting-edge innovation. While traditional solutions offer continuous glucose monitoring (CGM), we’re developing something far more advanced: Continuous Intelligent Glucose Monitoring (CiGM).
This next-generation technology goes beyond tracking. It not only monitors glucose levels in real time but also analyzes spikes, identifies patterns, and provides actionable insights. For instance, if your sugar levels spike, the system will suggest specific steps to bring it down—and monitor whether you actually take those actions. It becomes both a guide and a guardian.
At its core, CiGM is more than just a wearable. It’s a comprehensive lifestyle companion designed to help users monitor, manage, and actively control their glucose levels—transforming diabetes care from passive observation to proactive intervention and intelligent decision-making.
Q: How do you envision Sciverse evolving and expanding in the long term, both in terms of markets and capabilities?
A: Our vision for growth is clear—we aim to take this technology to diverse communities across the globe, ensuring it reaches every segment of society. At the heart of this vision lies our unwavering commitment to point-of-care diagnostics.
We are developing technologies that shift critical lab-based tests out of centralized facilities and place them directly in the hands of end-users—even in the most remote, underserved regions of rural India. Our goal is to simplify complex diagnostics into intuitive, one- or two-step processes that anyone can perform, regardless of their technical background.
By making advanced healthcare tools accessible, easy to use, and widely deployable, we’re breaking down barriers to diagnostics—and empowering individuals everywhere to take control of their health.
